1. The Role of Maintenance Therapy in Multiple Myeloma

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Components of Myeloma Therapy Transplant-Eligible Patients

4. VRd vs Rd: SWOG S0777 Data

5. MM Induction Therapy

6. Role of Carfilzomib in Induction Therapy

7. Summary: Induction Therapy

8. Maintenance Lenalidomide: Key Trials

9. Meta-Analysis: HRs for OS by Risk Subgroup

10. HOVON-65/GMMG-HD4: Bortezomib Induction and Maintenance by Cytogenetic Risk

11. Implementing Maintenance Therapy in Practice

12. Selected Maintenance Options in Transplant-Eligible Patients

13. Maintenance Regimens for Transplant-Ineligible Patients

14. FIRST Trial: Benefit With Continuous Len in Nontransplanted MM

15. SWOG S0777: RVD vs RD

16. Summary: Maintenance Therapy

17. Toxicities and Maintenance Therapy

18. Managing Complications

19. Future Directions in MM

20. Key Takeaways